Premium
New targets for antibody therapy of pediatric B cell lymphomas
Author(s) -
van Vuren Annelies,
MeyerWentrup Friederike
Publication year - 2014
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25193
Subject(s) - medicine , lymphoma , monoclonal antibody , monoclonal antibody therapy , antibody , b cell lymphoma , blood cancer , chemotherapy , oncology , antigen , targeted therapy , monoclonal , pediatric cancer , b cell , immunology , cancer
Antibody therapy has become standard of care for adult B cell lymphoma patients. It is a potentially less toxic and more targeted approach for lymphoma therapy and should therefore be applied to treat pediatric B cell lymphoma patients as well. In pediatric lymphoma patients, however, clinical experience with monoclonal antibodies is very limited. This is in part due to smaller patient numbers and very good outcome with conventional chemotherapy. In addition, pediatric patient and lymphoma biology differ significantly from that found in adults often precluding extrapolation of the adult experience to children. This review focuses on targeting pediatric B cell lymphoma with monoclonal antibody therapy. The special characteristics of B cell lymphomas found in children are reviewed and six potential new lymphoma target antigens are discussed. Pediatr Blood Cancer 2014;61:2158–2163. © 2014 Wiley Periodicals, Inc.